[SCHEDULE 13G/A] Coherus Oncology, Inc. Amended Passive Investment Disclosure

Coherus Oncology, Inc. Schedule 13G/A amendment shows the Timothy G. Youngquist 2020 Irrevocable Trust beneficially owns 12,790,800 shares of common stock, representing 8.267% of the class.

Rhea-AI Filing Summary

Coherus Oncology, Inc. Schedule 13G/A amendment shows the Timothy G. Youngquist 2020 Irrevocable Trust beneficially owns 12,790,800 shares of common stock, representing 8.267% of the class. The filing states this percentage is based on 154,217,609 shares outstanding as of April 16, 2026 and includes 500,000 shares underlying call options deemed outstanding for purposes of Rule 13d-3.

Insights

Institutional Ownership Analyst

Large trust reports an 8.267% stake in Coherus Oncology.

The filing identifies the Timothy G. Youngquist 2020 Irrevocable Trust as beneficial owner of 12,790,800 shares, representing 8.267% of the class based on April 16, 2026 outstanding shares.

Disclosure notes inclusion of 500,000 call-option shares for Rule 13d-3 purposes; cash‑flow treatment or planned dispositions are not stated in the excerpt.

Securities Compliance Specialist

Filing is an ownership disclosure amendment with trustee signature.

The Schedule 13G/A format and signature by a manager indicate a passive ownership disclosure under applicable rules; the Trust is identified and its address and voting/dispositive powers are listed.

The filing ties the percentage to the issuer's proxy-stated outstanding share count; this anchors the reported stake to an explicit April 16, 2026 baseline.

Key Figures

Beneficially owned: 12,790,800 shares Percent of class: 8.267% Shares outstanding (basis): 154,217,609 shares +1 more

4 metrics

Beneficially owned 12,790,800 shares Amount beneficially owned by the Trust

Percent of class 8.267% Percent of class based on outstanding shares as of <date>April 16, 2026</date>

Shares outstanding (basis) 154,217,609 shares Shares outstanding used to calculate percentage as of <date>April 16, 2026</date>

Underlying call options included 500,000 shares Call options exercisable within 60 days counted under Rule 13d-3

Key Terms

Schedule 13G/A, beneficially owned, Rule 13d-3, call options

4 terms

Schedule 13G/A regulatory

"Schedule 13G/A amendment showing passive beneficial ownership"

A Schedule 13G/A is an amended public filing with the U.S. securities regulator that updates a previous Schedule 13G, disclosing when an individual or group holds a substantial (typically over 5%) stake in a company and is claiming a passive, non‑controlling intent. Investors monitor these updates because rising or falling holdings can signal changing confidence, potential future moves, or shifts in voting power — like watching a public ledger where large shareholders quietly adjust their positions.

beneficially owned financial

"Amount beneficially owned: 12,790,800"

Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.

Rule 13d-3 regulatory

"underlying call options ... deemed outstanding for purposes of Rule 13d-3"

Rule 13d-3 defines who is treated as the beneficial owner of a company’s shares for U.S. securities disclosure rules — essentially anyone who has the power to vote or direct how shares are voted, or the power to buy or sell them, even if they don’t hold the certificates. For investors this matters because crossing certain ownership thresholds triggers public filing and disclosure obligations and signals potential control or influence, much like having the keys to a car implies you can drive it even if it’s registered to someone else.

call options financial

"Includes 500,000 shares underlying call options exercisable within 60 days"

A call option is a contract that gives its buyer the right, but not the obligation, to buy a specific number of shares at a predetermined price within a set time. Think of it like a refundable reservation to purchase a stock later at today’s agreed price: investors use calls to profit from expected price rises with smaller upfront cost than buying the stock outright, or to hedge and manage exposure, while the most they can lose is the amount paid for the contract.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/11/2026 - 09:21 AM Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 1)

Coherus Oncology, Inc.

(Name of Issuer)

Common Stock, par value $0.0001 per share

(Title of Class of Securities)

19249H103

(CUSIP Number)

02/05/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 19249H103

1

Names of Reporting Persons

Timothy G. Youngquist 2020 Irrevocable Trust

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power
6	Shared Voting Power
7	Sole Dispositive Power
8	Shared Dispositive Power

9

Aggregate Amount Beneficially Owned by Each Reporting Person

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

12

Type of Reporting Person (See Instructions)

Comment for Type of Reporting Person: The percentage reported is based on 154,217,609 shares of the Issuer's common stock outstanding as of April 16, 2026, as reported in the Issuer's Definitive Proxy Statement on Schedule 14A filed with the Securities and Exchange Commission on April 20, 2026. The shares reported herein are held by the Timothy G. Youngquist 2020 Irrevocable Trust, dated 2020, as amended and/or restated (the "Trust"), of which Trista Kragh is a trustee. Includes 500,000 shares of common stock underlying call options that constitute a right to acquire shares within 60 days for purposes of Rule 13d-3. For purposes of calculating the Reporting Person's percentage of class, such underlying shares are deemed outstanding.

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Coherus Oncology, Inc.
(b)	Address of issuer's principal executive offices: C/O DENNIS M. LANFEAR, C/O DENNIS M. LANFEAR, REDWOOD CITY, CALIFORNIA, 94065.
Item 2.
(a)	Name of person filing: Timothy G. Youngquist 2020 Irrevocable Trust
(b)	Address or principal business office or, if none, residence: 15581 Pine Ridge Road Fort Myers, Fl 33908
(c)	Citizenship: USA
(d)	Title of class of securities: Common Stock, par value $0.0001 per share
(e)	CUSIP No.: 19249H103
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 12,790,800
(b)	Percent of class: 8.267%
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 12,790,800
	(ii) Shared power to vote or to direct the vote: 0
	(iii) Sole power to dispose or to direct the disposition of: 12,790,800
	(iv) Shared power to dispose or to direct the disposition of: 0
Item 5.	Ownership of 5 Percent or Less of a Class.
	Ownership of 5 percent or less of a class
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required. Timothy G. Youngquist 2020 Irrevocable Trust
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	If a group has filed this schedule pursuant to §240.13d-1(b)(1)(ii)(J), so indicate under Item 3(j) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to §240.13d-1(c) or §240.13d-1(d), attach an exhibit stating the identity of each member of the group. Trust
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.	Certifications:
	Not Applicable

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Timothy G. Youngquist 2020 Irrevocable Trust

Signature:	Nolan Rheam
Name/Title:	Manager
Date:	05/11/2026